PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: OSO BioPharmaceuticals Manufacturing, LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

OSO BioPharmaceuticals to Sponsor Forum on Subcutaneous Biologic Drug Delivery Trends - The 2011 DCAT Week Biologics Forum will present regulatory and pharmaceutical industry leaders discussing current requirements, trends and best practices for subcutaneous biologic drug delivery systems
OSO BioPharmaceuticals to Sponsor Forum on Subcutaneous Biologic Drug Delivery Trends

 

NewswireToday - /newswire/ - Albuquerque, NM, United States, 2011/02/22 - The 2011 DCAT Week Biologics Forum will present regulatory and pharmaceutical industry leaders discussing current requirements, trends and best practices for subcutaneous biologic drug delivery systems.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

OSO BioPharmaceuticals Manufacturing, LLC, will sponsor the Biologics Forum taking place March 16 as part of DCAT Week.

OsoBio is a contract manufacturing organization focusing on biologic and pharmaceutical injectables. Headquartered in Albuquerque, N.M., OsoBio specializes in products that require complex handling, including highly potent compounds.

The 2011 DCAT Week Biologics Forum will present regulatory and pharmaceutical industry leaders discussing current requirements, trends and best practices for subcutaneous biologic drug delivery systems. Participants will learn about innovations in products, tools and practices, as well as practical applications with case studies.

“Methodologies for qualifying primary container and delivery devices remain somewhat vague, which is why discussing case studies and sharing best practices is useful within the pharmaceutical industry, ” said Stuart Rose, president and CEO of OsoBio. “OsoBio is pleased to sponsor an event that advances quality and safety knowledge in our industry, ultimately benefiting the patients we all seek to serve.”

DCAT Week – sponsored annually by the Drug, Chemical and Associated Technologies Association (DCAT) – is considered by many participating industry representatives to be one of the most important meetings of the year.

The Biologics Forum is scheduled to take place Wednesday, March 16, from 1:15 pm. to 4:30 pm. in the Empire Room at the Waldorf-Astoria Hotel in New York City. A networking reception will follow.

DCAT invites representatives from non-member companies with interests in biologics to attend this program and networking event for the DCAT member price of $99. For registration information, visit osobio.com/.

OsoBio surpasses quality-assurance expectations within our industry. Our employees are industry veterans who provide innovative solutions to our clients’ most difficult projects.

Contact: Milton Boyer, VP business development and sales, 706-694-2514

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: OSO BioPharmaceuticals Manufacturing, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


OSO BioPharmaceuticals to Sponsor Forum on Subcutaneous Biologic Drug Delivery Trends

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Karen Stinneford - Sinclair & Co. for OsoBio 
919-833-9102 kstinneford[.]sinclair-co.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any OSO BioPharmaceuticals Manufacturing, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From OSO BioPharmaceuticals Manufacturing, LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)